Assessment of diuretic effects and changes in plasma aldosterone concentration following oral administration of a single dose of furosemide or azosemide in healthy dogs

American Journal of Veterinary Research

Volumn 69, Issue 12, 2008, Pages 1664-1669

  Hori, Yasutomo ^a   Katou, Akiko ^a   Tsubaki, Mizuho ^a   Kanai, Kazutaka ^a   Nakao, Ruriko ^a   Hoshi, Fumio ^a   Itoh, Naoyuki ^a   Higuchi, Sei Ichi ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AZOSEMIDE; FUROSEMIDE; PLACEBO;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIURESIS; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG URINE LEVEL; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLACEBO EFFECT; POTASSIUM URINE LEVEL; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINGLE DRUG DOSE; SODIUM URINE LEVEL; TREATMENT DURATION; URINALYSIS; URINE VOLUME;

ADMINISTRATION, ORAL; ALDOSTERONE; ANIMALS; DIURETICS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FUROSEMIDE; MALE; SULFANILAMIDES;

ANIMALIA; BIFIDOBACTERIUM; CANIS FAMILIARIS;

EID: 57849167552     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.69.12.1664     Document Type: Article

References (27)

1. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2005;112:e154-e235.
2. Hori Y, Takusagawa F, Ikadai H, et al. Effects of oral administration of furosemide and torsemide in healthy dogs. Am J Vet Res 2007;68:1058-1063.
3. Abdallah JG, Schrier RW, Edelstein C, et al. Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(-)-cotransporter abundance: role of aldosterone. J Am Soc Nephrol 2001;12:1335-1341.
4. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation 2004;109:1680-1685.
5. Cataliotti A, Boerrigter G, Chen HH, et al. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure. Circulation 2002;105:639-644.
6. Kim GH, Na KY, Kim SY, et al. Up-regulation of organic anion transporter 1 protein is induced by chronic furosemide or hydrochlorothiazide infusion in rat kidney. Nephrol Dial Transplant 2003;18:1505-1511.
7. Na KY, Oh YK, Han JS, et al. Upregulation of Na+ transporter abundances in response to chronic thiazide or loop diuretic treatment in rats. Am J Physiol Renal Physiol 2003;284:F133-F143.
8. Paterna S, Di Pasquale P, Parrinello G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. Eur J Heart Fail 2000;2:305-313.
9. McCurley JM, Hanlon SU, Wei SK, et al. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 2004;44:1301-1307.
10. Brater DC, Day B, Anderson S, et al. Azosemide kinetics and dynamics. Clin Pharmacol Ther 1983;34:454-458.
11. Brater DC. Renal sites of action of azosemide. Clin Pharmacol Ther 1979;25:428-434.
12. Brater DC. Benefits and risks of torasemide in congestive heart failure and essential hypertension. Drug Saf 1996;14:104-120.
13. Greven J, Heidenreich O. Renal actions of azosemide. 1. Clearance investigations in dogs. Arzneimittelforschung 1981;31:346-350.
14. Tomiyama H, Nakayama T, Watanabe G, et al. Effects of short-acting and long-acting loop diuretics on heart rate variability in patients with chronic compensated congestive heart failure. Am Heart J 1999;137:543-548.
15. Kuzuya F. Phase 1 study of azosemide (SK-110): single- and multiple-dose study. Int J Clin Pharmacol Ther Toxicol 1983;21:10-23.
16. Suh OK, Kim SH, Lee MG. Pharmacokinetics and pharmacodynamics of azosemide. Biopharm Drug Dispos 2003;24:275-297.
17. Rado JP, Molhar Z, Hartai A, et al. Comparison of azosemide and furosemide in ascitic patients without and during administration of spironolactone. Int J Clin Pharmacol Ther Toxicol 1982;20:532-537.
18. Tsutsui T, Tsutamoto T, Maeda K, et al. Comparison of neurohumoral effects of short-acting and long-acting loop diuretics in patients with chronic congestive heart failure. J Cardiovasc Pharmacol 2001;38:S81-S85.
19. Yoshida J, Yamamoto K, Mano T, et al. Different effects of long - and short-acting loop diuretics on survival rate in Dahl high-salt heart failure model rats. Cardiovasc Res 2005;68:118-127.
20. Uechi M, Matsuoka M, Kuwajima E, et al. The effects of the loop diuretics furosemide and torasemide on diuresis in dogs and cats. J Vet Med Sci 2003;65:1057-1061.
21. Inoue T, Hayashi M, Inoue A, et al. Behavior of azosemide (SK-110) in the body. A study on ADME of azosemide in rats, rabbits, dogs and monkeys. Kiso to Rinsho (Jpn) 1984;18:5233-5244.
22. Cutler RE, Blair AD. Clinical pharmacokinetics of frusemide. Clin Pharmacokinet 1979;4:279-296.
23. Domanski M, Norman J, Pitt B, et al. Studies of left ventricular dysfunction. Diuretic use, progressive heart failure, and death in patients in the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 2003;42:705-708.
24. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
25. Flamenbaum W, Friedman R. Pharmacology, therapeutic efficacy, and adverse effects of bumetanide, a new "loop" diuretic. Pharmacotherapy 1982;2:213-222.
26. Tamano S, Hayashi M, Suzuki M, et al. A 26-week chronic toxicity study of azosemide (SK-110) in beagle dogs. Kiso to Rinsho (Jpn) 1984;18:5143-5175.
27. Horky K, Gregorova I, Dvorakova J. The effect of renin and aldosterone inhibition by beta-adrenergic blockade on the response to the new diuretic azosemide. Eur J Pharmacol 1981;69:439-446.